Aktienanalyse zu Aethlon Medical Inc (AEMD)AEMDAethlon Medical Inc

Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Aethlon Medical Inc (AEMD) is currently not a strong buy due to its recent performance and financial metrics. The stock has seen a significant decline of 57.09% year-to-date and an 82.07% drop over the past year, indicating a challenging environment. Although the company reported a narrower net loss of $1.55 million in Q1 2026, down from $1.76 million the previous year, the forward P/E ratio is 0.2074, suggesting potential undervaluation but also uncertainty in future earnings. The RSI is at 49.694, indicating a neutral position, and the stock is trading below its 200-day moving average of 8.361, which is a bearish signal. The main risk is the continued net losses, with the latest reported loss at $1.52 million for Q1 2027, which could impact investor confidence and stock performance.

1 analysts cover AEMD: 1 rate it Buy, 0 Hold and 0 Sell.